|Bid||6.30 x 1100|
|Ask||6.48 x 3200|
|Day's range||6.25 - 6.50|
|52-week range||5.45 - 23.85|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
SEATTLE, October 18, 2021--Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
NEW YORK, October 08, 2021--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER) on behalf of Omeros stockholders. Our investigation concerns whether Omeros has violated the federal securities laws and/or engaged in other unlawful business practices.
LOS ANGELES, October 06, 2021--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER) investors concerning the Company’s possible violations of the federal securities laws.